[ad_1]
Katherine Kurnit, MD, Gynecologic Oncology Researcher at MD Anderson Cancer Center, Compares the Benefits of Gastrointestinal (GI) Adjuvant Chemotherapy Treatments to Gynecologic Gynecologic (GYN) Treatments in Patients with Mucous Ovary Cancer .
The results of a recent retrospective study indicate that treatment with a GI-based regimen may be more beneficial than that of a GYN-based regimen in this patient population. Those who received the IG-based treatment scored significantly better in terms of progression-free survival and overall survival, said Kurnit, who was the lead author of the study.
These results, she adds, were somewhat unexpected. Although her team hypothesized that GI-based treatment regimens might lead to better outcomes, she did not expect the earnings difference to be as large as it was. In fact, Kurnit adds that she has more experience in using gynecologic-based diets than in those based on IG.
According to Kurnit, if it's an approach that doctors should consider using in the future, these data will actually change the treatment approach for these patients and considerations relating to chemotherapy as part of an adjuvant.
See more of the SGO 2019 Winter Meeting
Source link
